Prevalence, number of fractures, and hospital characteristics among the pediatric population with osteogenesis imperfecta: results from the nationwide registry of Türkiye.
Journal
Journal of pediatric orthopedics. Part B
ISSN: 1473-5865
Titre abrégé: J Pediatr Orthop B
Pays: United States
ID NLM: 9300904
Informations de publication
Date de publication:
17 Jun 2024
17 Jun 2024
Historique:
medline:
20
6
2024
pubmed:
20
6
2024
entrez:
20
6
2024
Statut:
aheadofprint
Résumé
Osteogenesis imperfecta is a rare connective tissue disorder with an estimated number of 4-20 cases per 100 000 inhabitants. Although the prevalence differs among regions, there are only a few number of national registry studies published previously. The aim of this study was to determine the prevalence of osteogenesis imperfecta among the pediatric age group in Türkiye, together with the patient and hospital characteristics. Via the e-health database of the Turkish Ministry of Health, we collected and retrospectively evaluated the medical records of the patients who were under 18 years of age with the diagnosis of osteogenesis imperfecta between 2016 and 2022. Total number of fractures, treatment modalities, and the hospital characteristics were also recorded. Two thousand seven hundred forty patients were extracted with a mean age of 9.77 ± 4.81 years. The prevalence of osteogenesis imperfecta in Türkiye among the pediatric population was calculated as 11.6 per 100 000 individuals. The median annual incidence was 31.5 per 100 000 live births between 2016 and 2022. There were 17.4 hospital admissions per patient per year. The mean age at the time of in-hospital mortality was 4.08 ± 5.03 years. The fracture rate per patient per year was 0.56 and conservative treatment was the most commonly preferred modality for all ages. This is the first registry-based nationwide study of osteogenesis imperfecta patients in Türkiye, providing important characteristics of the disease. Together with the help of the ongoing development of national health database systems, precision in patient identification would yield substantial benefits in terms of management of osteogenesis imperfecta.
Identifiants
pubmed: 38900105
doi: 10.1097/BPB.0000000000001192
pii: 01202412-990000000-00205
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Thomas IH, DiMeglio LA. Advances in the classification and treatment of osteogenesis imperfecta. Curr Osteoporos Rep 2016; 14:1–9.
Storoni S, Treurniet S, Maugeri A, Pals G, van den Aardweg JG, van der Pas SL, et al. Prevalence and hospital admissions in patients with osteogenesis imperfecta in the Netherlands: a nationwide registry study. Front Endocrinol (Lausanne) 2022; 13:869604.
Folkestad L, Hald JD, Canudas-Romo V, Gram J, Hermann AP, Langdahl B, et al. Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study. J Bone Miner Res 2016; 31:2159–2166.
Darba J, Marsa A. Hospital incidence, management and direct cost of osteogenesis imperfecta in Spain: a retrospective database analysis. J Med Econ 2020; 23:1435–1440.
Birinci SA. Digital opportunity for patients to manage their health: Turkey National Personal Health Record System (The e-Nabiz). Balkan Med J 2023; 40:215–221.
Biggin A, Munns CF. Long-term bisphosphonate therapy in osteogenesis imperfecta. Curr Osteoporos Rep 2017; 15:412–418.
Cho TJ, Ko JM, Kim H, Shin HI, Yoo WJ, Shin CH. Management of osteogenesis imperfecta: a multidisciplinary comprehensive approach. Clin Orthop Surg 2020; 12:417–429.
Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. Osteoporos Int 2016; 27:3427–3437.
Rossi V, Lee B, Marom R. Osteogenesis imperfecta: advancements in genetics and treatment. Curr Opin Pediatr 2019; 31:708–715.
Martin E, Shapiro JR. Osteogenesis imperfecta: epidemiology and pathophysiology. Curr Osteoporos Rep 2007; 5:91–97.
Valadares ER, Carneiro TB, Santos PM, Oliveira AC, Zabel B. What is new in genetics and osteogenesis imperfecta classification? J Pediatr (Rio J) 2014; 90:536–541.
Kolovos S, Javaid MK, Pinedo-Villanueva R. Hospital admissions of patients with osteogenesis imperfecta in the English NHS. Osteoporos Int 2021; 32:1207–1216.
Vitale MG, Matsumoto H, Kessler MW, Hoffmann W, Roye DP Jr. Osteogenesis imperfecta: determining the demographics and the predictors of death from an inpatient population. J Pediatr Orthop 2007; 27:228–232.
Antoniazzi F, Monti E, Venturi G, Franceschi R, Doro F, Gatti D, et al. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. Eur J Endocrinol 2010; 163:479–487.
Chevrel G, Cimaz R. Osteogenesis imperfecta: new treatment options. Curr Rheumatol Rep 2006; 8:474–479.
Brizola E, Shapiro JR. Bisphosphonate treatment of children and adults with osteogenesis imperfecta: unanswered questions. Calcif Tissue Int 2015; 97:101–103.
Pizones J, Plotkin H, Parra-Garcia JI, Alvarez P, Gutierrez P, Bueno A, et al. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. J Pediatr Orthop 2005; 25:332–335.
Shi CG, Zhang Y, Yuan W. Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: a systematic review and meta-analysis. Am J Ther 2016; 23:e894–e904.
Simm PJ, Biggin A, Zacharin MR, Rodda CP, Tham E, Siafarikas A, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health 2018; 54:223–233.
Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2014; 7:CD005088.
Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2016; 2016:CD005088.
Fassier FR. Osteogenesis imperfecta-who needs rodding surgery? Curr Osteoporos Rep 2021; 19:264–270.
Franzone JM, Shah SA, Wallace MJ, Kruse RW. Osteogenesis imperfecta: a pediatric orthopedic perspective. Orthop Clin North Am 2019; 50:193–209.
Laron D, Pandya NK. Advances in the orthopedic management of osteogenesis imperfecta. Orthop Clin North Am 2013; 44:565–573.
Sarikaya I, Seker A, Erdal OA, Gunay H, Inan M, Guler B. Using a corkscrew-tipped telescopic nail in the treatment of osteogenesis imperfecta: a biomechanical study and preliminary results of 17 consecutive cases. J Pediatr Orthop B 2019; 28:173–178.
Esposito P, Plotkin H. Surgical treatment of osteogenesis imperfecta: current concepts. Curr Opin Pediatr 2008; 20:52–57.
Birke O, Davies N, Latimer M, Little DG, Bellemore M. Experience with the Fassier-Duval telescopic rod: first 24 consecutive cases with a minimum of 1-year follow-up. J Pediatr Orthop 2011; 31:458–464.
Folkestad L, Hald JD, Ersboll AK, Gram J, Hermann AP, Langdahl B, et al. Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study. J Bone Miner Res 2017; 32:125–134.